Skip to main content
Top
Published in: Heart and Vessels 1/2014

01-01-2014 | Original Article

Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio

Authors: Satoshi Okumura, Masaki Sakakibara, Ryo Hayashida, Yasushi Jinno, Akihito Tanaka, Koji Okada, Mutsuharu Hayashi, Hideki Ishii, Toyoaki Murohara

Published in: Heart and Vessels | Issue 1/2014

Login to get access

Abstract

High low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol (L/H) ratio is associated with progressions of coronary arteriosclerosis and chronic kidney disease. On the other hand, renal function markedly declined after acute myocardial infarction (AMI). The aims of the present study were (1) to identify what type of patients with AMI would have high L/H ratio at follow-up and (2) to evaluate whether decline in renal function after AMI had accelerated or not in patients with high L/H ratio. The 190 eligible AMI patients who underwent primary percutaneous coronary intervention (PCI) and received atorvastatin (10 mg) were divided into one of two groups according to the L/H ratio at 6-month follow-up: L/H >2 group (n = 81) or L/H ≤2 group (n = 109). The characteristics on admission in the two groups were examined. Furthermore, changes in serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) during 1- and 6-month follow-up were compared between the two groups. L/H >2 group were significantly younger and had greater body mass index (BMI) and worse lipid profile on admission compared with L/H ≤2 group. Percentage increase in sCr and percentage decrease in eGFR during 1-month follow-up in L/H >2 group tended to be greater than in L/H ≤2 group, and those during 6-month follow-up were significantly greater (16.5 ± 2.77 vs. 9.79 ± 2.23 %, p = 0.03 and 11.8 ± 1.93 vs. 2.75 ± 3.85 %, p = 0.04, respectively). In AMI patients undergoing primary PCI, those who were young and had large BMI and poor lipid profile on admission were likely to have a high L/H ratio at follow-up despite statin therapy. In addition, the decline in renal function after AMI had significantly accelerated in patients with high L/H ratio.
Literature
1.
go back to reference Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499–508PubMedCrossRef Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499–508PubMedCrossRef
2.
go back to reference Matsumoto I, Miyake Y, Mizukawa M, Takagi Y (2011) Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 75:905–910PubMedCrossRef Matsumoto I, Miyake Y, Mizukawa M, Takagi Y (2011) Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 75:905–910PubMedCrossRef
3.
go back to reference Mulec H, Johnsen SA, Wiklund O, Björck S (1993) Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196–201PubMed Mulec H, Johnsen SA, Wiklund O, Björck S (1993) Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196–201PubMed
4.
go back to reference Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998–1004PubMedCrossRef Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998–1004PubMedCrossRef
5.
go back to reference Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908–1915PubMedCrossRef Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908–1915PubMedCrossRef
6.
go back to reference Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ (2005) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293–301CrossRef Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ (2005) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293–301CrossRef
7.
go back to reference Mänttäri M, Tiula E, Alikoski T, Manninen V (1995) Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670–675PubMedCrossRef Mänttäri M, Tiula E, Alikoski T, Manninen V (1995) Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670–675PubMedCrossRef
8.
go back to reference Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D (2003) Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24(5):412–420PubMedCrossRef Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D (2003) Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24(5):412–420PubMedCrossRef
9.
go back to reference Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718PubMedCrossRef Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718PubMedCrossRef
10.
go back to reference Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRef Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRef
11.
go back to reference Kanadaşi M, Çayli M, Demirtaş M, İnal T, Demor M, Koç M, Avkaroğullari M, Dönmez Y, Usal A, Alhan CC, Şan M (2006) The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome with low-density lipoprotein cholesterol. Heart Vessels 21:291–297PubMedCrossRef Kanadaşi M, Çayli M, Demirtaş M, İnal T, Demor M, Koç M, Avkaroğullari M, Dönmez Y, Usal A, Alhan CC, Şan M (2006) The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome with low-density lipoprotein cholesterol. Heart Vessels 21:291–297PubMedCrossRef
12.
go back to reference Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ, National Registry of Myocardial Infarction 4 Investigators (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611–616PubMedCrossRef Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ, National Registry of Myocardial Infarction 4 Investigators (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611–616PubMedCrossRef
13.
go back to reference Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171–178PubMedCrossRef Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171–178PubMedCrossRef
14.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef
15.
go back to reference Nakamura H, Mizuno K, MEGA Study Group (2008) Lowered ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol with lipid-lowering therapy associated with reduction of cardiovascular events in primary prevention: MEGA Study post hoc analysis. Circulation 118:S_1174 Nakamura H, Mizuno K, MEGA Study Group (2008) Lowered ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol with lipid-lowering therapy associated with reduction of cardiovascular events in primary prevention: MEGA Study post hoc analysis. Circulation 118:S_1174
16.
go back to reference Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D’Agostino RB, Vasan RS (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298(7):776–785PubMedCrossRef Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D’Agostino RB, Vasan RS (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298(7):776–785PubMedCrossRef
17.
go back to reference Franssen R, Monajemi H, Stoes ES, Kastelein JJ (2011) Obesity and dyslipidemia. Med Clin N Am 95(5):893–902PubMedCrossRef Franssen R, Monajemi H, Stoes ES, Kastelein JJ (2011) Obesity and dyslipidemia. Med Clin N Am 95(5):893–902PubMedCrossRef
18.
go back to reference Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A, Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97:1165–1171PubMedCrossRef Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A, Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97:1165–1171PubMedCrossRef
19.
go back to reference Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220–228PubMedCrossRef Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220–228PubMedCrossRef
20.
go back to reference Burne-Taney MJ, Liu M, Ascon D, Molls RR, Racusen L, Rabb H (2006) Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naïve mice: a possible mechanism linking early injury and progressive renal disease? Am J Physiol Renal Physiol 291:F981–F986PubMedCrossRef Burne-Taney MJ, Liu M, Ascon D, Molls RR, Racusen L, Rabb H (2006) Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naïve mice: a possible mechanism linking early injury and progressive renal disease? Am J Physiol Renal Physiol 291:F981–F986PubMedCrossRef
21.
go back to reference Hörbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, Sutton TA (2007) Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 293:F688–F695PubMedCrossRef Hörbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, Sutton TA (2007) Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 293:F688–F695PubMedCrossRef
22.
go back to reference Zager RA, Johnson AC, Becker K (2011) Acute unilateral ischemic injury induces progressive renal inflammation, lipid accumulation, histone modification, and “end-stage” kidney disease. Am J Physiol Renal Physiol 301:F1334–F1345PubMedCrossRef Zager RA, Johnson AC, Becker K (2011) Acute unilateral ischemic injury induces progressive renal inflammation, lipid accumulation, histone modification, and “end-stage” kidney disease. Am J Physiol Renal Physiol 301:F1334–F1345PubMedCrossRef
23.
go back to reference Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE (2009) Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int 76:1089–1097PubMedCrossRef Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE (2009) Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int 76:1089–1097PubMedCrossRef
24.
go back to reference Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG, University of Toronto Acute Kidney Injury Research Group (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302:1179–1185PubMedCrossRef Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG, University of Toronto Acute Kidney Injury Research Group (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302:1179–1185PubMedCrossRef
25.
go back to reference Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Hsu CY (2009) Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 76:893–899PubMedCentralPubMedCrossRef Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Hsu CY (2009) Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 76:893–899PubMedCentralPubMedCrossRef
26.
go back to reference Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ (2009) Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20:223–228PubMedCrossRef Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ (2009) Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20:223–228PubMedCrossRef
27.
go back to reference Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, Hong MK, Jang Y (2011) Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 97:1753–1757PubMedCrossRef Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, Hong MK, Jang Y (2011) Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 97:1753–1757PubMedCrossRef
28.
go back to reference Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP (2007) Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 1:8–14PubMedCentralPubMed Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP (2007) Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 1:8–14PubMedCentralPubMed
29.
go back to reference Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36:211–228PubMed Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36:211–228PubMed
30.
go back to reference Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R (2005) High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25:1206–1212PubMedCrossRef Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R (2005) High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25:1206–1212PubMedCrossRef
31.
go back to reference Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309–1311PubMedCrossRef Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309–1311PubMedCrossRef
32.
go back to reference Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53PubMedCrossRef Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53PubMedCrossRef
33.
go back to reference Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ (2011) The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58:2068–2075PubMedCrossRef Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ (2011) The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58:2068–2075PubMedCrossRef
34.
go back to reference Lee TM, Lin MS, Tsai CH, Chang NC (2005) Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 68:779–787PubMedCrossRef Lee TM, Lin MS, Tsai CH, Chang NC (2005) Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 68:779–787PubMedCrossRef
35.
go back to reference Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N (2000) Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 67:427–431PubMedCrossRef Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N (2000) Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 67:427–431PubMedCrossRef
37.
go back to reference Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L (2011) Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26:628–636PubMedCrossRef Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L (2011) Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26:628–636PubMedCrossRef
38.
go back to reference Lunder M, Ziberna L, Janić M, Jerin A, Skitek M, Sabovič M, Drevenšek G (2012) Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels. doi:10.1007/s00380-012-0259-0 PubMed Lunder M, Ziberna L, Janić M, Jerin A, Skitek M, Sabovič M, Drevenšek G (2012) Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels. doi:10.​1007/​s00380-012-0259-0 PubMed
39.
40.
go back to reference Fried LF (2008) Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74:571–576PubMedCrossRef Fried LF (2008) Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74:571–576PubMedCrossRef
41.
go back to reference D’Amico G (2006) Statins and renal disease: from primary prevention to renal replacement therapy. J Am Soc Nephrol 17:S148–S152PubMedCrossRef D’Amico G (2006) Statins and renal disease: from primary prevention to renal replacement therapy. J Am Soc Nephrol 17:S148–S152PubMedCrossRef
Metadata
Title
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio
Authors
Satoshi Okumura
Masaki Sakakibara
Ryo Hayashida
Yasushi Jinno
Akihito Tanaka
Koji Okada
Mutsuharu Hayashi
Hideki Ishii
Toyoaki Murohara
Publication date
01-01-2014
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 1/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-012-0321-y

Other articles of this Issue 1/2014

Heart and Vessels 1/2014 Go to the issue